From the Journals

VIDEO: Cystic fibrosis patients need earlier, more frequent colorectal cancer screening

View on the News

Susan Millard, MD, FCCP, comments on Cystic Fibrosis

According to the Cystic Fibrosis Foundation Patient Registry, more than 30,000 people are living with cystic fibrosis (CF ) in the United States. More than half of the CF population is over 18 years of age! It is extremely important to talk to patients about preventative medicine which was not a topic of conversation CF healthcare providers were adding to their management plan in the past.

Dr. Susan Millard


 

FROM GASTROENTEROLOGY

The new document reflects expert consensus on the currently available data, the panel said. As more data emerge, the recommendations might change.

“It is possible that different subpopulations will need more or less frequent schedules for rescreening and surveillance. Our recommendations are making an effort to balance the risk of missing advanced colorectal cancer and minimizing the burden and risk of too frequent examinations.”

None of the panel members had any financial disclosures.

SOURCE: Hadjiliadis D et al. Gastroenterology. 2017 Dec 28. doi. org/10.1053/j.gastro.2017.12.012

Pages

Recommended Reading

Study: Test carcinoembryonic antigen in colon cancer after surgery
MDedge Hematology and Oncology
S-1 regimen noninferior to other frontline mCRC options
MDedge Hematology and Oncology
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Hematology and Oncology
Circulating tumor cell assay shows promise for colorectal cancer screening
MDedge Hematology and Oncology
FDA approves lutetium Lu 177 dotatate for GEP-NETs
MDedge Hematology and Oncology
Combination immunotherapy is active in dMMR/MSI-H metastatic colorectal cancer
MDedge Hematology and Oncology
Pembrolizumab plus SBRT shows promise for advanced solid tumors
MDedge Hematology and Oncology
First-line ramucirumab nets small PFS benefit in gastric cancer
MDedge Hematology and Oncology
Postcolonoscopy cancer rates persist despite quality protocols
MDedge Hematology and Oncology
Right-sided CRC has poorer disease-free survival after adjuvant chemo
MDedge Hematology and Oncology